Search

Your search keyword '"Tsuta, Koji"' showing total 1,294 results
Start Over Author "Tsuta, Koji"
1,294 results on '"Tsuta, Koji"'

15. Evaluating Cellularity Estimation Methods: Comparing AI Counting with Pathologists’ Visual Estimates

Author

Kiyuna, Tomoharu, primary, Cosatto, Eric, additional, Hatanaka, Kanako C., additional, Yokose, Tomoyuki, additional, Tsuta, Koji, additional, Motoi, Noriko, additional, Makita, Keishi, additional, Shimizu, Ai, additional, Shinohara, Toshiya, additional, Suzuki, Akira, additional, Takakuwa, Emi, additional, Takakuwa, Yasunari, additional, Tsuji, Takahiro, additional, Tsujiwaki, Mitsuhiro, additional, Yanai, Mitsuru, additional, Yuzawa, Sayaka, additional, Ogura, Maki, additional, and Hatanaka, Yutaka, additional

Published
2024
Full Text
View/download PDF

16. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Author

Yoh, Kiyotaka, Matsumoto, Shingo, Furuya, Naoki, Nishino, Kazumi, Miyamoto, Shingo, Oizumi, Satoshi, Okamoto, Norio, Itani, Hidetoshi, Kuyama, Shoichi, Nakamura, Atsushi, Nishi, Koichi, Fukuda, Ikue, Tsuta, Koji, Hayashi, Yuichiro, Motoi, Noriko, Ishii, Genichiro, and Goto, Koichi

Published
2021
Full Text
View/download PDF

18. Giant cell glioblastoma with lipogenic differentiation in a patient with neurofibromatosis type 1: A case report.

Author

Shintaku, Masayuki, Hashiba, Tetsuo, Nonaka, Masahiro, Asai, Akio, and Tsuta, Koji

Subjects
NEUROFIBROMATOSIS 1, FRONTAL lobe, GENETIC mutation, GLIOBLASTOMA multiforme, SYNAPTOPHYSIN, DNA mismatch repair
Abstract

A 45‐year‐old woman with neurofibromatosis type 1 (NF1) developed a tumor in the left frontal lobe that showed features of giant cell glioblastoma (GC‐GB). In addition to the typical GC‐GB features, the tumor showed lipogenic differentiation, with many atypical lipoblasts and mature adipocytes. Tumor cells, including the lipogenic cells, were immunoreactive for GFAP, S‐100 protein, ATRX, and p53. They were negative for IDH1‐R132H, BRAF V600E, synaptophysin, NeuN, p16, mismatch repair proteins, and CD34. The patient is free from recurrence at approximately two years postoperatively. This is the fifth reported case of NF1‐associated GC‐GB (the second adult case). NF1 gene mutation might have played a role in the pathogenesis of lipogenic differentiation of GC‐GB. The differential diagnosis of lipidized GC‐GB from gliosarcoma or anaplastic pleomorphic xanthoastrocytoma is briefly discussed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Alveolar adenoma with a single cyst: A case report

Author

Matsui, Hiroshi, primary, Utsumi, Takahiro, additional, Maru, Natsumi, additional, Taniguchi, Yohei, additional, Saito, Tomohito, additional, Hino, Haruaki, additional, Ishida, Kaori, additional, Tsuta, Koji, additional, and Murakawa, Tomohiro, additional

Published
2024
Full Text
View/download PDF

26. Comprehensive genomic profiles of small cell lung cancer

Author

George, Julie, Lim, Jing Shan, Jang, Se Jin, Cun, Yupeng, Ozretić, Luka, Kong, Gu, Leenders, Frauke, Lu, Xin, Fernández-Cuesta, Lynnette, Bosco, Graziella, Müller, Christian, Dahmen, Ilona, Jahchan, Nadine S, Park, Kwon-Sik, Yang, Dian, Karnezis, Anthony N, Vaka, Dedeepya, Torres, Angela, Wang, Maia Segura, Korbel, Jan O, Menon, Roopika, Chun, Sung-Min, Kim, Deokhoon, Wilkerson, Matt, Hayes, Neil, Engelmann, David, Pützer, Brigitte, Bos, Marc, Michels, Sebastian, Vlasic, Ignacija, Seidel, Danila, Pinther, Berit, Schaub, Philipp, Becker, Christian, Altmüller, Janine, Yokota, Jun, Kohno, Takashi, Iwakawa, Reika, Tsuta, Koji, Noguchi, Masayuki, Muley, Thomas, Hoffmann, Hans, Schnabel, Philipp A, Petersen, Iver, Chen, Yuan, Soltermann, Alex, Tischler, Verena, Choi, Chang-min, Kim, Yong-Hee, Massion, Pierre P, Zou, Yong, Jovanovic, Dragana, Kontic, Milica, Wright, Gavin M, Russell, Prudence A, Solomon, Benjamin, Koch, Ina, Lindner, Michael, Muscarella, Lucia A, la Torre, Annamaria, Field, John K, Jakopovic, Marko, Knezevic, Jelena, Castaños-Vélez, Esmeralda, Roz, Luca, Pastorino, Ugo, Brustugun, Odd-Terje, Lund-Iversen, Marius, Thunnissen, Erik, Köhler, Jens, Schuler, Martin, Botling, Johan, Sandelin, Martin, Sanchez-Cespedes, Montserrat, Salvesen, Helga B, Achter, Viktor, Lang, Ulrich, Bogus, Magdalena, Schneider, Peter M, Zander, Thomas, Ansén, Sascha, Hallek, Michael, Wolf, Jürgen, Vingron, Martin, Yatabe, Yasushi, Travis, William D, Nürnberg, Peter, Reinhardt, Christian, Perner, Sven, Heukamp, Lukas, Büttner, Reinhard, Haas, Stefan A, Brambilla, Elisabeth, Peifer, Martin, Sage, Julien, and Thomas, Roman K

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Oncology and Carcinogenesis, Human Genome, Cancer, Rare Diseases, Lung, Lung Cancer, Aetiology, 2.1 Biological and endogenous factors, Alleles, Animals, Cell Line, Tumor, Chromosome Breakpoints, Cyclin D1, DNA-Binding Proteins, Disease Models, Animal, Female, Gene Expression Profiling, Genome, Human, Genomics, Humans, Lung Neoplasms, Male, Mice, Mutation, Neurosecretory Systems, Nuclear Proteins, Receptors, Notch, Retinoblastoma Protein, Signal Transduction, Small Cell Lung Carcinoma, Tumor Protein p73, Tumor Suppressor Protein p53, Tumor Suppressor Proteins, General Science & Technology
Abstract

We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Δex2/3. In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.

Published
2015

30. Correction to: Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes

Author

Ohe, Chisato, Yoshida, Takashi, Amin, Mahul B., Atsumi, Naho, Ikeda, Junichi, Saiga, Kazuho, Noda, Yuri, Yasukochi, Yoshiki, Ohashi, Riuko, Ohsugi, Haruyuki, Higasa, Koichiro, Kinoshita, Hidefumi, and Tsuta, Koji

Published
2022
Full Text
View/download PDF

31. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma

Author

Sekine, Shigeki, Kiyono, Tohru, Ryo, Eijitsu, Ogawa, Reiko, Wakai, Susumu, Ichikawa, Hitoshi, Suzuki, Koyu, Arai, Satoru, Tsuta, Koji, Ishida, Mitsuaki, Sasajima, Yuko, Goshima, Naoki, Yamazaki, Naoya, and Mori, Taisuke

Subjects
Transcription (Genetics), Immunohistochemistry, Skin cancer, Skin, RNA sequencing, Genetic research, Fluorescence, Polymerase chain reaction, RNA, Tumors, Health care industry
Abstract

Poroma is a benign skin tumor exhibiting terminal sweat gland duct differentiation. The present study aimed to explore the potential role of gene fusions in the tumorigenesis of poromas. RNA sequencing and reverse transcription PCR identified highly recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poromas (92/104 lesions, 88.5%) and their rare malignant counterpart, porocarcinomas (7/11 lesions, 63.6%). A WWTR1-NUTM1 fusion was identified in a single lesion of poroma. Fluorescence in situ hybridization confirmed genomic rearrangements involving these genetic loci. Immunohistochemical staining could readily identify the YAP1 fusion products as nuclear expression of the N-terminal portion of YAP1 with a lack of the C-terminal portion. YAP1 and WWTR1, also known as YAP and TAZ, respectively, encode paralogous transcriptional activators of TEAD, which are negatively regulated by the Hippo signaling pathway. The YAP1 and WWTR1 fusions strongly transactivated a TEAD reporter and promoted anchorage-independent growth, confirming their tumorigenic roles. Our results demonstrate the frequent presence of transforming YAP1 fusions in poromas and porocarcinomas and suggest YAP1/TEAD-dependent transcription as a candidate therapeutic target against porocarcinoma., Introduction Poroma is a skin adnexal tumor exhibiting features of the terminal sweat gland duct (1, 2). It typically presents as a solitary sessile nodule on the soles and palms [...]

Published
2019
Full Text
View/download PDF

41. Supplemental Table S2 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma

Author

Saito, Motonobu, primary, Shiraishi, Kouya, primary, Matsumoto, Kenji, primary, Schetter, Aaron J., primary, Ogata-Kawata, Hiroko, primary, Tsuchiya, Naoto, primary, Kunitoh, Hideo, primary, Nokihara, Hiroshi, primary, Watanabe, Shun-ichi, primary, Tsuta, Koji, primary, Kumamoto, Kensuke, primary, Takenoshita, Seiichi, primary, Yokota, Jun, primary, Harris, Curtis C., primary, and Kohno, Takashi, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 2 from Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Author

Okano, Tetsuya, primary, Kondo, Tadashi, primary, Fujii, Kiyonaga, primary, Nishimura, Toshihide, primary, Takano, Toshimi, primary, Ohe, Yuichiro, primary, Tsuta, Koji, primary, Matsuno, Yoshihiro, primary, Gemma, Akihiko, primary, Kato, Harbumi, primary, Kudoh, Shoji, primary, and Hirohashi, Setsuo, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figures 1 - 5 from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma

Author

Nakaoku, Takashi, primary, Tsuta, Koji, primary, Ichikawa, Hitoshi, primary, Shiraishi, Kouya, primary, Sakamoto, Hiromi, primary, Enari, Masato, primary, Furuta, Koh, primary, Shimada, Yoko, primary, Ogiwara, Hideaki, primary, Watanabe, Shun-ichi, primary, Nokihara, Hiroshi, primary, Yasuda, Kazuki, primary, Hiramoto, Masaki, primary, Nammo, Takao, primary, Ishigame, Teruhide, primary, Schetter, Aaron J., primary, Okayama, Hirokazu, primary, Harris, Curtis C., primary, Kim, Young Hak, primary, Mishima, Michiaki, primary, Yokota, Jun, primary, Yoshida, Teruhiko, primary, and Kohno, Takashi, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table S2 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

Author

George, Julie, primary, Saito, Motonobu, primary, Tsuta, Koji, primary, Iwakawa, Reika, primary, Shiraishi, Kouya, primary, Scheel, Andreas H., primary, Uchida, Shinsuke, primary, Watanabe, Shun-ichi, primary, Nishikawa, Ryo, primary, Noguchi, Masayuki, primary, Peifer, Martin, primary, Jang, Se Jin, primary, Petersen, Iver, primary, Büttner, Reinhard, primary, Harris, Curtis C., primary, Yokota, Jun, primary, Thomas, Roman K., primary, and Kohno, Takashi, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Materials and Methods from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma

Author

Nakaoku, Takashi, primary, Tsuta, Koji, primary, Ichikawa, Hitoshi, primary, Shiraishi, Kouya, primary, Sakamoto, Hiromi, primary, Enari, Masato, primary, Furuta, Koh, primary, Shimada, Yoko, primary, Ogiwara, Hideaki, primary, Watanabe, Shun-ichi, primary, Nokihara, Hiroshi, primary, Yasuda, Kazuki, primary, Hiramoto, Masaki, primary, Nammo, Takao, primary, Ishigame, Teruhide, primary, Schetter, Aaron J., primary, Okayama, Hirokazu, primary, Harris, Curtis C., primary, Kim, Young Hak, primary, Mishima, Michiaki, primary, Yokota, Jun, primary, Yoshida, Teruhiko, primary, and Kohno, Takashi, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 3 from Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Author

Okano, Tetsuya, primary, Kondo, Tadashi, primary, Fujii, Kiyonaga, primary, Nishimura, Toshihide, primary, Takano, Toshimi, primary, Ohe, Yuichiro, primary, Tsuta, Koji, primary, Matsuno, Yoshihiro, primary, Gemma, Akihiko, primary, Kato, Harbumi, primary, Kudoh, Shoji, primary, and Hirohashi, Setsuo, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 3 from Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Author

Okano, Tetsuya, primary, Kondo, Tadashi, primary, Fujii, Kiyonaga, primary, Nishimura, Toshihide, primary, Takano, Toshimi, primary, Ohe, Yuichiro, primary, Tsuta, Koji, primary, Matsuno, Yoshihiro, primary, Gemma, Akihiko, primary, Kato, Harbumi, primary, Kudoh, Shoji, primary, and Hirohashi, Setsuo, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Text from Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Author

Okano, Tetsuya, primary, Kondo, Tadashi, primary, Fujii, Kiyonaga, primary, Nishimura, Toshihide, primary, Takano, Toshimi, primary, Ohe, Yuichiro, primary, Tsuta, Koji, primary, Matsuno, Yoshihiro, primary, Gemma, Akihiko, primary, Kato, Harbumi, primary, Kudoh, Shoji, primary, and Hirohashi, Setsuo, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Fig S3 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

Author

George, Julie, primary, Saito, Motonobu, primary, Tsuta, Koji, primary, Iwakawa, Reika, primary, Shiraishi, Kouya, primary, Scheel, Andreas H., primary, Uchida, Shinsuke, primary, Watanabe, Shun-ichi, primary, Nishikawa, Ryo, primary, Noguchi, Masayuki, primary, Peifer, Martin, primary, Jang, Se Jin, primary, Petersen, Iver, primary, Büttner, Reinhard, primary, Harris, Curtis C., primary, Yokota, Jun, primary, Thomas, Roman K., primary, and Kohno, Takashi, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 2 from Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Author

Okano, Tetsuya, primary, Kondo, Tadashi, primary, Fujii, Kiyonaga, primary, Nishimura, Toshihide, primary, Takano, Toshimi, primary, Ohe, Yuichiro, primary, Tsuta, Koji, primary, Matsuno, Yoshihiro, primary, Gemma, Akihiko, primary, Kato, Harbumi, primary, Kudoh, Shoji, primary, and Hirohashi, Setsuo, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results